Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

image
Business Standard
177 22
Business Standard

Dr Reddy's Lab rises 2.3%

BS Reporter  |  Mumbai 

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

RECOMMENDED FOR YOU

Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

image
Business Standard
177 22

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

Widgets Magazine

More News

STOCK WATCH

Company Price() Chg(%)
Indoco Remedies 299.90 13.97
Tech Mahindra 528.55 10.29
Yamini Invest 40.05 7.81
Greenply Inds. 212.60 7.62
Trident 50.65 6.97
> More on BSE Gainers
Company Price() Chg(%)
Indoco Remedies 303.90 15.97
Tech Mahindra 528.50 10.05
Greenply Inds. 213.30 7.75
Trident 50.70 7.19
Canara Bank 193.35 6.35
> More on NSE Gainers
Company Price() Chg(%)
VRL Logistics 275.45 -12.58
G S F C 73.35 -7.91
Bliss GVS Pharma 95.20 -7.26
SE Investments 173.05 -6.46
Cipla 470.30 -4.97
> More on BSE Gainers
Company Price() Chg(%)
VRL Logistics 276.20 -12.25
G S F C 73.55 -7.66
Bliss GVS Pharma 95.20 -6.94
Cipla 469.80 -4.91
Amara Raja Batt. 850.60 -4.89
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard